Dhumal Rohit, Vijaykumar Tushara, Dighe Vikas, Selkar Nilakash, Chawda Mukesh, Vahlia Mahesh, Vanage Geeta
National Centre for Preclinical Reproductive and Genetic Toxicology, National Institute for Research in Reproductive Health, Mumbai, India.
J Ayurveda Integr Med. 2013 Jul;4(3):158-64. doi: 10.4103/0975-9476.118706.
Reverse pharmacology for drug development has been highly productive and cost-effective in recent past as it is based on the documented therapeutic effects of plants in ancient texts. Afrodet Plus(®) is formulated for the treatment of male infertility, which contains ancient herbo-minerals. Its efficacy and safety are validated through this animal study in reverse pharmacology mode.
This study was undertaken to evaluate efficacy and safety of an Ayurvedic formulation Afrodet Plus(®) in adult male rats.
Twelve male rats (Holtzman) between 8 and 10 weeks of age were randomly selected and animals were assigned to a control and two treatment groups. Dosing was performed daily. Various parameters such as weekly body weight, hematology, serum testosterone levels, epididymal sperm count, and efficiency of Daily Sperm Production (DSP) were evaluated.
It was found that epididymal sperm count had significantly increased in both low-dose (+27.39%) and high-dose (+40.5%) groups as compared to control group. The DSP also showed an increase of 43.7% at high dose of 180 mg/kg body weight as compared to the control group. An increase in sperm motility and especially progressive motility was observed when evaluated by Computer Assisted Semen Analyzer. Histological evaluation of testicular tissue for spermatogenic index revealed that the index had increased in treatment group as compared to control group.
This study revealed that oral administration of Afrodet Plus(®) resulted in significant increase in DSP in the testis along with increase in epididymal sperm count and progressive motility as compared to control group without producing any treatment-related adverse effects. These findings provide the documentary evidence that the use of Afrodet Plus(®) at 90 and 180 mg/kg body weight is effective and safe for the treatment of male infertility especially to improve sperm count and progressive motility.
药物研发中的反向药理学在过去成效显著且具有成本效益，因为它基于古代文献中记载的植物治疗效果。Afrodet Plus（®）被配制成用于治疗男性不育症，含有古老的草药矿物质成分。通过这种反向药理学模式的动物研究验证了其疗效和安全性。
本研究旨在评估阿育吠陀配方药Afrodet Plus（®）对成年雄性大鼠的疗效和安全性。
随机选取12只8至10周龄的雄性大鼠（霍尔兹曼大鼠），并将动物分为对照组和两个治疗组。每天给药。评估了各种参数，如每周体重、血液学、血清睾酮水平、附睾精子计数以及每日精子生成效率（DSP）。
发现与对照组相比，低剂量组（+27.39%）和高剂量组（+40.5%）的附睾精子计数均显著增加。与对照组相比，体重180mg/kg的高剂量组DSP也增加了43.7%。通过计算机辅助精液分析仪评估时，观察到精子活力增加，尤其是进行性活力增加。对睾丸组织的生精指数进行组织学评估发现，与对照组相比，治疗组的指数有所增加。
本研究表明，与对照组相比，口服Afrodet Plus（®）可使睾丸中的DSP显著增加，同时附睾精子计数和进行性活力增加，且未产生任何与治疗相关的不良反应。这些发现提供了文献证据，表明体重90mg/kg和180mg/kg的Afrodet Plus（®）用于治疗男性不育症，尤其是提高精子计数和进行性活力是有效且安全的。
